Averting a malaria disaster in Africa: where does the buck stop?

Averting a malaria disaster in Africa: where does the buck stop?

The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly. Combination therapy has been suggested as being an availa...

Full description

Bibliographic Details
Main Authors:	Whitty Christopher J.M., Allan Richard, Wiseman Virginia, Ochola Sam, Nakyanzi-Mugisha Maria Veronicah, Vonhm Benjamin, Mwita Mahemba, Miaka Constantin, Oloo Aggrey, Premji Zul, Burgess Craig, Mutabingwa Theonest K.
Format:	Article
Language:	English
Published:	The World Health Organization 2004-01-01
Series:	Bulletin of the World Health Organization
Subjects:	Malaria, Falciparum/drug therapy Antimalarials/economics Drug therapy, Combination Artemisinins/economics Drug costs Patient acceptance of health care Financing, Organized Africa
Online Access:	http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862004000500012

Similar Items

Averting a malaria disaster in Africa: where does the buck stop?
by: Christopher J.M. Whitty, et al.

The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage <i>P. falciparum</i> Parasites, DMPK Properties, and the Case for Artemiside
by: Liezl Gibhard, et al.
Published: (2021-12-01)

Impact of parasite genomic dynamics on the sensitivity of Plasmodium falciparum isolates to piperaquine and other antimalarial drugs
by: Dancan M. Wakoli, et al.
Published: (2022-11-01)

Resistance to Artemisinin Combination Therapies (ACTs): Do Not Forget the Partner Drug!
by: Christian Nsanzabana
Published: (2019-02-01)

Antagonistic antimalarial properties of a methoxyamino chalcone derivative and 3-hydroxypyridinones in combination with dihydroartemisinin against Plasmodium falciparum
by: Tanyaluck Kampoun, et al.
Published: (2023-04-01)

Artemisia scoparia – A new source of artemisinin
by: Aditi Singh, et al.
Published: (2010-06-01)

Drug resistant falciparum malaria and the use of artesunate-based combinations : focus on clinical trials sponsored by TDR
by: Walter R.J. Taylor, Jean Rigal & Piero L. Olliaro
Published: (2003-09-01)

Prevalence of Clinical Artesunate Resistance among Cases of Complicated Malaria in Southern Odisha, India
by: Sindhusuta Das, et al.
Published: (2020-09-01)

Putative molecular markers of Plasmodium falciparum resistance to antimalarial drugs in malaria parasites from Ghana
by: Sena Adzoa Matrevi, et al.
Published: (2024-02-01)

Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo
by: Gauthier Mesia Kahunu, et al.
Published: (2024-02-01)

New approaches in antimalarial drug discovery and development: a review
by: Anna Caroline C Aguiar, et al.
Published: (2012-11-01)

Discovery of new targets for antimalarial chemotherapy
by: Grellier P., et al.
Published: (2008-09-01)

Capacity Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance Monitoring in Africa Network
by: Eric S. Halsey, et al.
Published: (2017-12-01)

Artemisinin
Published: (2014-07-01)

Genomic Epidemiology of Antimalarial Drug Resistance in Plasmodium falciparum in Southern China
by: Fang Huang, et al.
Published: (2021-01-01)

Substandard artemisinin-based antimalarial medicines in licensed retail pharmaceutical outlets in Ghana
by: M. El-Duah & K. Ofori-Kwakye
Published: (2012-09-01)

Malaria and safety issues associated with antimalarial drugs
by: A. S. Kazakov, et al.
Published: (2018-02-01)

Methylene Blue-Based Combination Therapy with Amodiaquine Prevents Severe Malaria in an Experimental Rodent Model
by: Jérôme Dormoi, et al.
Published: (2022-09-01)

Molecular assessment of kelch13 non-synonymous mutations in Plasmodium falciparum isolates from Central African Republic (2017–2019)
by: Romaric Nzoumbou-Boko, et al.
Published: (2020-05-01)

New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells
by: Diana Duarte, et al.
Published: (2020-12-01)

Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action
by: Diana Duarte, et al.
Published: (2022-10-01)

Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells
by: Diana Duarte, et al.
Published: (2022-10-01)

Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies
by: Guilherme Eduardo de Souza, et al.
Published: (2019-12-01)

Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
by: The WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group
Published: (2022-03-01)

Breaking the cycle of malaria treatment failure
by: Maciej F. Boni, et al.
Published: (2022-12-01)

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
by: Zhaowu Ma, et al.
Published: (2021-12-01)

Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018
by: Arlindo Chidimatembue, et al.
Published: (2021-10-01)

Profiling of the anti-malarial drug candidate SC83288 against artemisinins in Plasmodium falciparum
by: Maëlle Duffey, et al.
Published: (2018-03-01)

The influence of biological, epidemiological, and treatment factors on the establishment and spread of drug-resistant Plasmodium falciparum
by: Thiery Masserey, et al.
Published: (2022-07-01)

Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville
by: Ndounga Mathieu, et al.
Published: (2013-02-01)

A resistência à cloroquina e a busca de antimalariais entre as décadas de 1960 e 1980 Chloroquine resistance and the search for antimalarial drugs from the 1960s to 1980s
by: Ivone Manzali de Sá
Published: (2011-06-01)

Host-directed therapy, an untapped opportunity for antimalarial intervention
by: Ling Wei, et al.
Published: (2021-10-01)

Malaria situation and elimination in Africa with specific focus on Zimbabwe: a systematic review
by: Zakio Makuvara, et al.
Published: (2024-12-01)

A framework for stakeholder engagement in the adoption of new anti-malarial treatments in Africa: a case study of Nigeria
by: Olugbenga Ayodeji Mokuolu, et al.
Published: (2023-06-01)

Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo
by: Brice Pembet Singana, et al.
Published: (2022-05-01)

Artemisinin resistance: Cause for worry?
by: Anurag Khera, et al.
Published: (2019-01-01)

Kelly Chibale: Learning to Fail Your Way to Success
by: Lukas Meier
Published: (2023-09-01)

Prevalence of Plasmodium falciparum delayed clearance associated polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubp1) genes in Ghanaian isolates
by: Tryphena Adams, et al.
Published: (2018-03-01)

Efficacy and safety of Artemisinin Combination Therapy for the treatment of uncomplicated Plasmodium falciparum malaria across international borders of India
by: Swati Sinha, et al.
Published: (2024-01-01)

Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria
by: Jamsen Kris M, et al.
Published: (2012-07-01)